Abstract
There is evidence that angiogenesis plays an important role in the progression of multiple myeloma (MM). Hepatocyte growth factor (HGF) and tumor necrosis factor-α (TNF-α) are cytokines that potently stimulate angiogenesis. We evaluated the microvascular density (MVD) of bone marrow biopsies (after immunostaining with anti-CD34 antibodies) and serum levels of HGF and TNF-α in 43 patients with newly diagnosed MM. Twenty-four of these patients reached a plateau phase after treatment and were reevaluated for MVD, HGF and TNF-α. MVD values and serum levels of HGF and TNF-α were elevated in newly diagnosed MM patients in comparison with healthy controls. Pre-treatment MVD, HGF and TNF-α increased with advancing stage of MM disease. In patients reaching the plateau phase, a significant reduction in MVD, HGF and TNF-α levels occurred. A positive correlation was noted between pre-treatment MVD and serum levels of TNF-α and lactic dehydrogenase but not with HGF. However, HGF strongly correlated with β2-microglobulin (β2M), TNF-α and lactate dehydrogenase (LDH). We conclude that angiogenesis in MM, as expressed by the bone marrow MVD and the serum levels of angiogenic molecules such as HGF and TNF-α, increases with advancing clinical stage and decreases after effective chemotherapy.
References
1 Folkman J. New perspectives in clinical oncology from angiogenesis research. Eur J Cancer 1996; 14:2534–9.10.1016/S0959-8049(96)00423-6Search in Google Scholar
2 Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis: correlation with invasive breast carcinoma. N Engl J Med 1991; 324:1–8.10.1056/NEJM199101033240101Search in Google Scholar
3 Galindo Gallego M, Fernandez Acenero MJ, Sanz Ortega J, Aljama A. Vascular enumeration as a prognosticator for colorectal carcinoma. Eur J Cancer 2000; 36:55–60.10.1016/S0959-8049(99)00243-9Search in Google Scholar
4 Williams JK, Carlson GW, Cohen C, Derose PB, Hunter S, Jurkiewicz MJ. Tumor angiogenesis as a prognostic factor in oral cavity tumors. Am J Surg 1994; 168:373–80.10.1016/S0002-9610(05)80079-0Search in Google Scholar
5 Acenero MJ, Gonzalez JF, Galledo MG, Ballesteros BA. Vascular enumeration as a prognosticator for invasive breast carcinoma. J Clin Oncol 1998; 16:1684–8.10.1200/JCO.1998.16.5.1684Search in Google Scholar PubMed
6 Sezer O, Jakob C, Eucker J, Niemoller K, Gatz F, Wernecke K, et al. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. Eur J Haematol 2001; 66:83–8.10.1034/j.1600-0609.2001.00348.xSearch in Google Scholar PubMed
7 Alexandrakis MG, Passam FH, Boula A, Christophoridou A, Aloizos G, Roussou P, et al. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma. Ann Haematol 2003; 82:19–23.10.1007/s00277-002-0558-0Search in Google Scholar PubMed
8 Perez Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 1997; 150:815–21.Search in Google Scholar
9 Bertolini F, Paolucci M, Peccatori F, Cinieri S, Agazzi A, Ferrucci PF, et al. Angiogenic growth factors and endostatin in non Hodgkin’s lymphoma. Br J Haematol 1999; 106:504–9.10.1046/j.1365-2141.1999.01547.xSearch in Google Scholar PubMed
10 Anderson KC, Jones RM, Morimoto C, Leavitt P, Barut BA. Response pattern of purified myeloma cells to hematopoietic growth factors. Blood 1989; 73:1915–24.10.1182/blood.V73.7.1915.1915Search in Google Scholar
11 Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med 1997; 336:1657–64.10.1056/NEJM199706053362307Search in Google Scholar PubMed
12 Alexandrakis MG, Passam FH, Ganotakis ES, Sfiridaki K, Xilouri I, Perisinakis K, et al. The clinical and prognostic significance of erythrocyte sedimentation rate (ESR) serum interleukin-6 (IL-6) and acute phase protein levels in multiple myeloma. Clin Lab Haematol 2003; 25:41–6.10.1046/j.1365-2257.2003.00492.xSearch in Google Scholar PubMed
13 Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ. Interleukin-6 induces the expression of vascular endothelial growth factor. J Biol Chem 1996; 271:736–41.10.1074/jbc.271.2.736Search in Google Scholar PubMed
14 Carter A, Merchav S, Silvian-Draxler I, Tatarsky I. The role of interleukin-1 and tumour necrosis factor-α in human multiple myeloma. Br J Haematol 1990; 74:424–31.10.1111/j.1365-2141.1990.tb06330.xSearch in Google Scholar PubMed
15 Grant DS, Kleinman HK, Goldberg ID, Bhargava MM, Nickoloff BJ, Kinsella JL, et al. Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci USA 1993; 90:1937–41.10.1073/pnas.90.5.1937Search in Google Scholar PubMed PubMed Central
16 Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L, et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 1992; 119:629–41.10.1083/jcb.119.3.629Search in Google Scholar PubMed PubMed Central
17 Stoker M, Gherardi E, Perryman M, Gray J. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 1987; 327:239–42.10.1038/327239a0Search in Google Scholar PubMed
18 Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991; 251:802–4.10.1126/science.1846706Search in Google Scholar PubMed
19 Borset M, Lien E, Espevik T, Helseth E, Waage A, Sundan A. Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-MET in human myeloma cell lines. J Biol Chem 1996; 271:24655–61.10.1074/jbc.271.40.24655Search in Google Scholar PubMed
20 Seidel C, Borset M, Turesson I, Abildgaard N, Sundan A, Waage A. Elevated serum concentrations of the hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. Blood 1998; 91:806–12.10.1182/blood.V91.3.806Search in Google Scholar
21 Borset M, Hjorth-Hansen H, Seidel C, Sundan A, Waage A. Hepatocyte growth factor and its receptor c-met in multiple myeloma. Blood 1996; 88:3998–4004.10.1182/blood.V88.10.3998.bloodjournal88103998Search in Google Scholar
22 Vacca A, Ribatti D, Presta M, Minischetti M, Iurlaro N, Ria R, et al. Bone marrow neovascularization, plasma cell angiogenic potential and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999; 93:3064–73.10.1182/blood.V93.9.3064.409k07_3064_3073Search in Google Scholar
23 Chung YS, Maeda K, Sowa M. Prognostic value of angiogenesis in gastro-intestinal tumours. Eur J Cancer 1996; 32A:2501–5.10.1016/S0959-8049(96)00382-6Search in Google Scholar
24 Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992; 84:1875–87.10.1093/jnci/84.24.1875Search in Google Scholar
25 Pruneri G, Ponzoni M, Ferreri AJ, Decarli N, Tresoldi M, Raggi F, et al. Microvessel density, a surrogate marker of angiogenesis is significantly related to survival in multiple myeloma patients. Br J Haematol 2002; 118:817–20.10.1046/j.1365-2141.2002.03654.xSearch in Google Scholar
26 Durie BGM, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975; 36:842–54.10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-USearch in Google Scholar
27 Taylor CR, RJ Cote. Immunomicroscopy; a diagnostic tool for the surgical pathologist. Philadelphia: WB Saunders, 1994.Search in Google Scholar
28 Bland M. An introduction to medical statistics, 3rd ed. Oxford UK: OUP, 2000:261.Search in Google Scholar
29 Dosquet C, Coudert MC, Lepage E, Cabane J, Richard F. Are angiogenic factors, cytokines and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma. Clin Cancer Res 1997; 3:2451–8.Search in Google Scholar
30 Leek RD, Landers R, Fox SB, Ng F, Harris AL, Lewis CE. Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. Br J Cancer 1998; 77:2246–51.10.1038/bjc.1998.373Search in Google Scholar
31 Laroche M, Brousset P, Ludot I, Mazieres B, Thiechart M, Attal M. Increased vascularization in myeloma. Eur J Haematol 2001; 66:89–93.10.1034/j.1600-0609.2001.00191.xSearch in Google Scholar
32 Rajkumar SV, Leong T, Roche PC, Fonseca R, Dispenzieri A, Lacy MQ, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 2000; 6:3111–6.Search in Google Scholar
33 Iwasaki T, Hamano T, Ogata A, Hashimoto N, Kitano M, Kakishita E. Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma. Br J Haematol 2002; 116:796–802.10.1046/j.0007-1048.2002.03364.xSearch in Google Scholar
34 Dimopoulos MA, Barlogie B, Smith TL, Alexanian R. High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern Med 1991; 115:931–5.10.7326/0003-4819-115-12-931Search in Google Scholar
35 Turesson I, Abildgaard N, Ahlgren T, Dahl I, Holmberg E, Hjorth M, et al. Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors. Br J Haematol 1999; 106:1005–12.10.1046/j.1365-2141.1999.01651.xSearch in Google Scholar
36 Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance and normal bone marrow plasma cell. Blood 2002; 99:1745–57.10.1182/blood.V99.5.1745Search in Google Scholar
37 Seidel C, Lenhoff S, Brabrand S, Anderson G, Standal T, Lanng-Nielsen J, et al. Hepatocyte growth factor in myeloma patients treated with high-dose chemotherapy, for the Nordic Myeloma Study Group. Br J Haematol 2002; 119:672–6.10.1046/j.1365-2141.2002.03898.xSearch in Google Scholar PubMed
38 Sezer O, Niemoller K, Kaufmann O, Eucker J, Jakob C, Zavrski I, Possinger K. Decrease of bone marrow angiogenesis in myeloma patients achieving a remission after chemotherapy. Eur J Haematol 2001; 66:238–4410.1034/j.1600-0609.2001.066004238.xSearch in Google Scholar PubMed
© Walter de Gruyter
